Murphy & Mullick Capital Management Corp Makes New Investment in Pfizer Inc. (NYSE:PFE)

Murphy & Mullick Capital Management Corp bought a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 8,875 shares of the biopharmaceutical company’s stock, valued at approximately $235,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Meiji Yasuda Asset Management Co Ltd. boosted its stake in shares of Pfizer by 1.6% in the 4th quarter. Meiji Yasuda Asset Management Co Ltd. now owns 194,055 shares of the biopharmaceutical company’s stock valued at $5,148,000 after buying an additional 2,974 shares during the period. PKS Advisory Services LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $324,000. Zions Bancorporation N.A. lifted its stake in Pfizer by 3.6% in the fourth quarter. Zions Bancorporation N.A. now owns 212,680 shares of the biopharmaceutical company’s stock worth $5,642,000 after acquiring an additional 7,374 shares during the last quarter. Modern Wealth Management LLC increased its position in shares of Pfizer by 48.7% in the 4th quarter. Modern Wealth Management LLC now owns 42,336 shares of the biopharmaceutical company’s stock valued at $1,095,000 after purchasing an additional 13,865 shares during the last quarter. Finally, Segall Bryant & Hamill LLC raised its holdings in shares of Pfizer by 4.3% in the 4th quarter. Segall Bryant & Hamill LLC now owns 76,539 shares of the biopharmaceutical company’s stock valued at $2,031,000 after purchasing an additional 3,177 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.56 on Wednesday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market capitalization of $144.96 billion, a price-to-earnings ratio of 18.13, a PEG ratio of 0.64 and a beta of 0.61. The company has a 50-day simple moving average of $26.14 and a 200-day simple moving average of $27.00. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the business earned $0.10 EPS. The firm’s revenue was up 24.7% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PFE shares. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.